Growth factor receptors-mediated signal pathways, such as those activated by EGFR and ErbB-2, play an active role in breast cancer cell growth, survival, cell cycle deregulation, tumor initiation, and tumor progression/metastasis. Additionally, there is accumulated evidence demonstrating a close relationship between cancer progression and energy metabolism. Metabolic deregulation has even lately been considered as the seventh hallmark of cancers in addition to the well-established six hallmarks. The development and the utilization of novel molecular therapies requires an understanding of both signal aberrations and metabolic regulation, and of how they relate to each other. This renewal program project grant (PPG) aims at understanding signaling pathways of a few key molecules that play critical roles in breast tumor progression and metabolic regulation. The immediate goals of this PPG are to understand the EGFR family-mediated signaling pathways and metabolic regulation in the initiation and progression of breast cancer. This PPG consists of four interactive projects supported by one administrative core. Each of the four projects has its own unique set of specific aims that target at the common theme and are interdependent on components of other projects in the PPG. Project 1 will evaluate pathways of kinase-dependent and -independent of EGFR that link to cancer and metabolic regulation. Project 2 plans to exploit role of EGFR family in mammary tumorigenesis and metastasis in transgenic mice models. Project 3 will examine the role of Rab 25 in breast cancer bioenergetics and autophagy. Project 4 will investigate metabolic deregulation by 14-3-3^ and mammary tumor progression/metastasis. The long-term goals of this PPG are to understand how grovirth factor receptorsmediated pathways may contribute to breast cancer progression. In addition to traditional signal pathways, this renewal PPG also addresses how metabolic regulation may be regulated by growth factor receptors and involved in breast cancer progression. The outcome of this PPG will advance our understanding of the effect of growth factor receptor-mediated signaling on metabolic regulation and breast cancer progression and may shed light on new directions for breast cancer therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Woodhouse, Elizabeth
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Boulay, Pierre-Luc; Mitchell, Louise; Turpin, Jason et al. (2016) Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression. Cancer Res 76:2662-74
Mitra, Shreya; Federico, Lorenzo; Zhao, Wei et al. (2016) Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. Oncotarget 7:40252-40265
Wang, Yan; Hsu, Jung-Mao; Kang, Ya'an et al. (2016) Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Cancer Res 76:7049-7058
Hsu, Jennifer L; Hung, Mien-Chie (2016) The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev :
Li, Chia-Wei; Xia, Weiya; Lim, Seung-Oe et al. (2016) AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res 76:1451-62
Chen, Mei-Kuang; Hung, Mien-Chie (2016) Regulation of therapeutic resistance in cancers by receptor tyrosine kinases. Am J Cancer Res 6:827-42
Lucenay, Kimberly S; Doostan, Iman; Karakas, Cansu et al. (2016) Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Res 76:2406-18
Du, Yi; Yamaguchi, Hirohito; Wei, Yongkun et al. (2016) Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med 22:194-201
Turpin, J; Ling, C; Crosby, E J et al. (2016) The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Oncogene 35:6053-6064
Jones, Laura M; Broz, Miranda L; Ranger, Jill J et al. (2016) STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. Cancer Res 76:1416-28

Showing the most recent 10 out of 195 publications